Fidelity International’s Neurocrine Biosciences NBIX Stock Holding History

Fidelity International’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.12M	Sell	6,655 -97	-1%	-$14.4K	﹤0.01%	830
2026 Q1	$890K	Buy	+6,752	New	+$896K	﹤0.01%	834
2025 Q4	–	Sell	-1,454	Closed	-$204K	–	1058
2025 Q3	$204K	Sell	1,454 -2,564	-64%	-$347K	﹤0.01%	872
2025 Q2	$505K	Sell	4,018 -111	-3%	-$12.7K	﹤0.01%	796
2025 Q1	$457K	Sell	4,129 -10,288	-71%	-$1.3M	﹤0.01%	795
2024 Q4	$1.97M	Buy	14,417 +2,452	+20%	+$303K	﹤0.01%	680
2024 Q3	$1.38M	Sell	11,965 -2,697	-18%	-$370K	﹤0.01%	713
2024 Q2	$2.02M	Buy	+14,662	New	+$2.01M	﹤0.01%	689
2021 Q1	–	Sell	-135	Closed	-$13K	–	1053
2020 Q4	$13K	Buy	+135	New	+$13K	﹤0.01%	805
2020 Q1	–	Sell	-53	Closed	-$6K	–	931
2019 Q4	$6K	Buy	+53	New	+$5.55K	﹤0.01%	767

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity International's NBIX Position: Q2 2026 in Review

Fidelity International reduced its Neurocrine Biosciences (NBIX) stake by 1.4% in Q2 2026, selling an estimated $14.4K and leaving 6,655 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #830.

Fidelity International first reported a position in NBIX in Q4 2019 and has held it in 10 quarters since. The position peaked at $2.02M in Q2 2024. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Fidelity International held 6,655 shares of Neurocrine Biosciences worth $1.12M as of Q2 2026.
Fidelity International sold 97 Neurocrine Biosciences shares in Q2 2026, an estimated $14.4K.
Neurocrine Biosciences made up ﹤0.01% of Fidelity International's portfolio in Q2 2026, its #830 holding.
Fidelity International first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 10 quarters since.
Fidelity International's Neurocrine Biosciences position peaked at $2.02M in Q2 2024.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Fidelity International's 13F filing for Q2 2026, filed 13 Aug 2026.